FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
An FDA advisory committee is reviewing Moderna's mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older. Clinical data suggests the vaccine is effective, and experts believe mRNA technology could allow for faster production in response to viral mutations.
Why it matters
This represents a potential shift in public health strategy, utilizing pandemic-proven technology to improve seasonal influenza protection.
In a study of 40,000 people age 50 and older, Moderna’s mRNA vaccine reduced flu cases by about 27% compared to those given another routinely used vaccine brand. Photograph: Eileen T Meslar/Chicago Tribune via Getty Images View image in fullscreen In a study of 40,000 people age 50 and older, Moderna’s mRNA vaccine reduced flu cases by about 27% compared to those given another routinely used vaccine brand. Photograph: Eileen T Meslar/Chicago Tribune via Getty Images US healthcare FDA panel considers a first-of-its-kind flu vaccine using mRNA technology Moderna seeks FDA approval of its new shot, mFlusvia, as option for 50 and older
The article presents the regulatory process and clinical data neutrally.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in